ERRATUM

Sachio Suzuki · Hidehiro Oka · Nobuyuki Kawano
Satoshi Tanaka · Satoshi Utsuki · Kiyotaka Fujii

Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas

Brain Tumor Pathol (2001) 18:151–154

Table 1 (Pathological diagnosis, location, operation, irradiation, and follow-up on patients with ependymomas, p. 152), and Table 2 (Percent expression of MIB-1 and p53 in ependymomas, p. 153) were in error. The corrected clinical data are shown in the following tables.

Table 1. Pathological diagnosis, location, operation, irradiation, and follow-up on patients with ependymomas

Pathological diagnosis	Number of cases	Location			Operation			Irradiation	Mean duration of follow-up (months)
		Suprat.	Infrat.	Sp. cord	Total	Subtotal	Partial		
Ependymoma (grade I)	1	0	0	1	1	0	0	0	251
Ependymoma (grade II)	23	2	13	8	12	6	5	11	75
Ordinary	11	1	6	4	5	3	3	5	93
Cellular	1	0	1	0	0	0	1	1	186
Papillary	1	0	0	1	0	1	0	1	3
Clear-cell	7	1	6	0	4	2	1	4	79
Tanycytic	3	0	0	3	3	0	0	0	92
Anaplastic (grade III)	5	5	0	0	1	3	1	3	44

suprat., supratentorial; infrat., infratentorial; sp. cord, spinal cord; total, total resection; subtotal, subtotal resection; partial, partial resection

Table 2. Percent expression of MIB-1 and p53 in ependymomas

Pathological diagnosis	Case	MIB-1 (%)	p53 (%)
Myxopapillary (grade I)	1	0.8	0.4
Ependymoma (grade II)	23	3.1 ± 2.6	4.3 ± 7.1
Ordinary	11	2.3 ± 2.0	1.8 ± 1.5
Cellular	1	2.6	3.4
Papillary	1	5.5	4.2
Clear-cell	7	4.0 ± 2.3	4.6 ± 3.3
Tanycytic	3	1.0 ± 0.8	0.4 ± 0.6
Anaplastic (grade III)	5	13.0 ± 12.6	19.0 ± 15.4

S. Suzuki (✉) · H. Oka · S. Tanaka · S. Utsuki · K. Fujii
Department of Neurosurgery, Kitasato University School of
Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan
Tel. +81-42-778-8111; Fax +81-42-778-8441

N. Kawano
Isobe Clinic, Sagamihara, Kanagawa, Japan